TherapeuticsMD, Inc. (TXMD): R&D Expense

Annual figures by period end, from SEC filings.

Older than the company's other figures. The latest R&D Expense is for the year ended 2021-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$7.09M
Year ended 2021-12-31
-36.2%
3-year compound annual growth
-33.4%
5-year compound annual growth
n/m
10-year compound annual growth
$72.04M2011-12-31: $107.2K2012-12-31: $4.49M2013-12-31: $13.55M2014-12-31: $43.22M2015-12-31: $72.04M2016-12-31: $53.94M2017-12-31: $33.85M2018-12-31: $27.30M2019-12-31: $19.79M2020-12-31: $10.43M2021-12-31: $7.09M$7.09M
2011-12-31 R&D Expense (USD) 2021-12-31
Period endedR&D ExpenseChange YoYSource filing
2021-12-31$7.09M-32.1%2022-03-23, From 2021-01-01
2020-12-31$10.43M-47.3%2022-03-23, From 2020-01-01
2019-12-31$19.79M-27.5%2022-03-23, From 2019-01-01
2018-12-31$27.30M-19.4%2021-03-04, From 2018-01-01
2017-12-31$33.85M-37.2%2020-02-24, From 2017-01-01
2016-12-31$53.94M-25.1%2019-02-27, From 2016-01-01
2015-12-31$72.04M+66.7%2018-02-23, From 2015-01-01
2014-12-31$43.22M+218.9%2017-02-28, From 2014-01-01
2013-12-31$13.55M+201.7%2016-02-26, From 2013-01-01
2012-12-31$4.49Mn/m2015-03-12, From 2012-01-01
2011-12-31$107.2Kn/a2014-03-05, From 2011-01-01